Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $1,605,934.11 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the business’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the completion of the transaction, the insider directly owned 53,500 shares in the company, valued at approximately $1,889,085. This represents a 45.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $199,500.00.

NewAmsterdam Pharma Stock Down 2.1%

NewAmsterdam Pharma stock opened at $34.28 on Friday. The stock has a 50-day simple moving average of $34.05 and a 200 day simple moving average of $32.88. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -19.81 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Royal Bank Of Canada upped their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, The Goldman Sachs Group raised their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $46.55.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. boosted its stake in NewAmsterdam Pharma by 1.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after acquiring an additional 241,818 shares during the last quarter. Capital World Investors raised its holdings in NewAmsterdam Pharma by 1.6% in the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after purchasing an additional 161,289 shares during the period. Jennison Associates LLC boosted its position in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after buying an additional 697,129 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.